Showing 91-100 of 2074 results for "".
Women in Dermatology With Brooke Jackson, MD
https://practicaldermatology.com/topics/practice-management/women-in-dermatology-with-brooke-jackson-md/23218/Physician Spotlight: Lindsey A. Bordone, MD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-lindsey-a-bordone-md/23216/Ronald B. Prussick, MD, FRCPC
https://practicaldermatology.com/topics/general-topics/ronald-b-prussick-md-frcpc/21299/Physician Spotlight: Roy Geronemus, MD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-roy-geronemus-md/23151/Physician Spotlight: Gary Goldenberg, MD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-gary-goldenberg-md/20897/Perspective on the dermatologist's role in recommending lifestyle changes with patients.Approval for Evolus; Remembering Vic Narurkar, MD
https://practicaldermatology.com/topics/practice-management/dermwiretv-approval-for-evolus-remembering-vic-narurkar-md/19553/The FDA has approved Jeuveau, the lead product from Evolus, Inc. David Moatazedi, President and CEO of Evolus, and Michael Jafar, Chief Marketing Officer at Evolus, comment on market potential for the new product.Twenty-eight percent of physicians say the prior authorization process required by healConsiderations for Treatment Downtime After Laser Therapy in Scar Repair
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/considerations-for-treatment-downtime-after-laser-therapy-in-scar-repair-/18625/E. Victor Ross, MD discusses how treatment downtime influences his approach for treating scars. His goal, he said, is to achieve the highest degree of efficacy possible with laser used as mono- or combination therapy while being mindful of patients' comfort levels with the associated recovery periodEmerging Vitiligo Therapies
https://practicaldermatology.com/conferences/maui-derm-2022/emerging-vitiligo-therapies/20047/It’s really an exciting time to be treating vitiligo, says John E. Harris, MD, PhD. He reviews Phase 2 and 3 clinical trials for ruxolitinib, a topical JAK inhibitor, and the hope that the FDA could soon approve it for the treatment of vitiligo. He also discusses other possible targeted treatments iCOVID-19 Impact: Navigating Clinical Research
https://practicaldermatology.com/series/dermatology-dispatches/covid-19-impact-navigating-clinical-research/19771/Conducting clinical research studies is challenging as the majority of Americans are under stay-at-home orders for the forseeable future due to the COVID-19 pandemic, says Todd E. Schlesinger, MD. He suggests trialists do their best to say in contact with clinical research organizations, sponsors, aPatient Surveys: When and Why
https://practicaldermatology.com/topics/practice-management/patient-surveys-when-and-why/19112/Todd E. Schlesinger, MD, discusses the benefits of patient surveys and offers tips to get the most out of surveys. Sometimes negative survey responses offer value to the practice--if you use the feedback to improve. Coverage from Vegas Cosmetic Surgery 2014.